GcMAF Patient Monitoring


GcMAF has been used, with encouraging results, in many types of cancers at all stages. However, the challenge is to accurately assess the patients situation, so that GcMAF dosage can be guided intelligently.

Scans that track tumour size are the most reliable indicator of tumour burden. Ultrasound is non-toxic and accurate but cannot always find the lesions, so is good for monitoring an indicative tumour for response to treatment, but not good for accurate diagnosis. A Magnetic scan (MRI) is accurate and quite safe but does not image the lungs well. A Radiation scan (PET with radioactive glucose tracer) is the gold standard for imaging cancer in the body as the tracer accumulates in cancer cells due to their increased requirment for glucose. PET scans should however be limited in number, due to concerns over radiation poisoning.

Conventional cancer markers in the blood should continue to be used an indicators of cancer burden except PSA, which most often indicates other prostate disorders.

Vitamin D levels must be monitored, as experience has shown that GcMAF does not appear to work when blood levels of vitamin D are lower than 100nmol/L. It is suggested that blood levels are kept between 150 and 250nmol/L.

With regards to the patient´s genotype as far as VDR gene polymorphisms are concerned, people with bb/FF VDR genotypes (about 80% of the population) respond the best, the Bb/Ff (about 20% of the population) responds about half as well as the bb/FF genotype, and the uncommon BB/ff genotype (about 1% of the population) is reported not to respond at all (1). The worse your genotype, the more GcMAF you need. However, we do not recommend you spend time with a VDR gene polymorphism test. Simply start GcMAF treatment, and if response is slow, increase the dose.

Finally, the prognosis for all types of cancers is dependent upon the nutritional and inflammatory status of the patient and that can be monitored by the Prognostic Inflammatory and Nutritional Index (PINI) (2).

The PINI score therefore can become part of the laboratory assessment during GcMAF treatment and together with Nagalase testing and VDR gene polymorphism determination, can help monitor the response of each individual patient allowing adjustment of the dose and the frequency of administration in order to obtain the optimum results. (3).

Nagalase Testing

It has been reported to us from several reliable sources that practical experience with testing cancer patients for Nagalase has shown that it does not accurately reflect tumor burden.

We no longer recommend the Nagalase test.

Monocyte Count

A patients monocyte count will generally rise in the early stages of GcMAF treatment and indicates a response to GcMAF.

Note: Monocytes in the blood vessels become Macrophages in the tissues.

Prognostic Inflammatory and Nutritional Index (PINI) (2)

Calculated by dividing the product of serum alpha-1-glycoprotein and CRP levels by that of albumin and pre-albumin.

alpha-1-glycoprotein (mg/dl) x CRP (mg/dl)
albumin (g/dl) x prealbumin (mg/dl)

Where PINI
> 30 = Predicts a very high risk of complications
[21-30] = Predicts a high risk of complications
[11-20] = Predicts an intermediate risk
[1-10] = Predicts a low risk
< 1 = Normal

Your doctor can organise the blood tests required for the PINI score.

Genotyping - Vitamin D Receptor (VDR) polymorphisms

Testing in Europe R.E.D. Laboratories. Belgium

(1) Pacini S, Morucci G, Punzi T, Gulisano M, Ruggiero M, Amato M, Aterini S.
Effect of paricalcitol and GcMAF on angiogenesis and human peripheral blood mononuclear cell proliferation and signaling.
J Nephrol. 2012 Jul-Aug;25(4):577-81. doi: 10.5301/jn.5000035.
Link to Abstract    Full Article

(2) Ariele Fabris, Paolo Biagioni, Tiziana Punzi, Gabriele Morucci, Massimo Gulisano, Stefania Pacini and Marco Ruggiero.
Role of Angiotensin-Converting Enzyme and Vitamin D Receptor Gene Polymorphisms in Cancer Anorexia-Cachexia Syndrome.
American Journal of Immunology, 2012, 8 (3), 65-70. DOI: 10.3844/ajisp.2012.65.70
Link to Abstract    Full Article

(3) Lynda Thyer, Emma Ward, Rodney Smith, Jacopo J.V. Branca, Gabriele Morucci, Massimo Gulisano, David Noakes and Stefania Pacini.
Therapeutic Effects of Highly Purified De-Glycosylated GcMAF in the Immunotherapy of Patients with Chronic Diseases.
American Journal of Immunology, 2012, 9 (3), 78-84. DOI: 10.3844/ajisp.2013.78.84
Link to Abstract    Full Article